GSK - GlaxoSmithKline: latest news - GoINPHARMA
Sunday, 24 March 2019 - 18:40

GSK – GlaxoSmithKline

Verily (Alphabet) raises funds for $1 billion

Verily, a company focusing on data collection and elaboration for disease prevention, part of Alphabet (Google) group, has announced it has successfully closed a $1bn funding round. The key funders taking part in it include private equity Silver Lake and…

An analysis of new GSK-Pfizer’s new OTC JV

GlaxoSmithKline and Pfizer yesterday surprised markets by announcing the creation of a joint venture with each group’s Consumer Health divisions. The new entity will be a $10bn-revenue giant, with a 25% EBIT and a 7.3% market share in the world…

GSK acquires Tesaro for $5.1bn

After having announced job cuts, reorganizing plans and pipeline rationalization for countless times, GlaxoSmithKline’s CEO Emma Walmsley today announced, as trading started in Europe, her first acquisition. Indeed, GSK informed it has acquired US-based biotech Tesaro for $5.1bn in cash….

Excellent quarter for GlaxoSmithKline

Britain-based GlaxoSmithKline today has announced a quarter exceeding analysts’ expectations, especially thanks to excellent sales performances from the new herpes vaccine, whose revenues have offset the market share loss due to Advair’s patent expiring in the US: the blockbuster is…

New positive clinical results from ViiV’s (GSK) two-drug HIV therapy

ViiV, a subsidiary of GSK’s, yesterday evening announced results from the Phase III clinical trial Flair, assessing the efficacy of its two-drug (cabotegravir, rilpivirine) therapy on HIV patients. Specifically, the results show that the two-drug regime has the same efficacy…

GSK announces new spate of job cuts

GlaxoSmithKline has announced it plans to downsize its Sterile Injectables division, a move that will drastically reduce the workforce in Ulverston site (UK), that focuses on sterile liquids. Ulverston employs 347 people, 191 of which will lose their jobs starting…

Nestlé, Unilever and Coca-Cola targeting GSK’s Horlicks ($3bn)

The Financial Times has reported today that the three major FMCG multinationals–Nestlé, Unilever and Coca-Cola–have submitted a bid to GlaxoSmithKline for Horlicks, an Indian manufacturer of malted drinks. The offers are approximately worth $2.5bn-$3bn, the article reports. GSK has allowed…

Coca-Cola preparing $4bn offer for GSK’s Horlicks

The British daily The Telegraph yesterday reported that Coca-Cola Co is about to submit a multi-billion offer for GlaxoSmithKline’s Horlicks Ltd. Horlicks is part of GSK group and produces malted energy drinks. It is worth at least $4bn, analysts say….

GSK announces new positive clinical data for two-drug HIV treatment

ViiV Healthcare, a subsidiary of  GlaxoSmithKline’s focusing on HIV, has reported today, before trading started in Europe, results from the Phase III Atlas clinical trial, enrolling 618 patients with HIV, treated with a cabotegravir-rilpivirine injected treatment for 48 weeks. The…

GSK closes down manufacturing site in Bangladesh with 1,000 employees

GlaxoSmithKline will definitely close down its Bangladesh production site, which will result in 1,000 employees to lose their jobs. The Britain-based multinational will continue its business in the country through GSK Bangladesh Ltd, of which the state-run Investment Corporation of…

GSK announces GBP400m price cut plan

The GSK group CEO Emma Walmsley today has announced a price cut plan aimed at saving a minimum of GBP400m pa before 2021. The cuts will mainly affect the supply chain, but also costs of administration departments will be significantly…

GSK acquires part of 23andme for $300m to stimulate drug discovery

GlaxoSmithKline has announced today it has acquired part of the California-based biotech engineering company 23andme from investors Sequoia Capital and Google Ventures, plus some minor investors. As part of the agreement, GSK will pay $300m to access 23andme’s rich database,…

GSK explores splitting group into two

The Financial Times has published between yesterday and today a series of articles about the recent decision by the major shareholders of GlaxoSmithKline’s to explore splitting the UK-based pharma group into two. The company’s shareholders have considered that creating two…

Coca Cola, Nestle and Kraft Heinz in talks with GSK

UK-based The Sunday Telegraph has reported today that The Coca-Cola Company, Kraft Heinz and Nestle have started negotiating with GlaxoSmithKline in order to acquire Horlicks. GSK last March informed the financial community that it was planning to dismiss the Horlicks…

First results from GSK’s combo HIV therapy

ViiV, a subsidiary of  GlaxoSmithKline’s having also Pfizer and Shionogi as shareholders, has reported positive early results from the Phase III Gemini-1 and Gemini-2 clinical trials, enrolling 1,400 patients with HIV, treated with a dolutegravir-lamivudine combo therapy for 48 weeks….

Worrisome first quarter from GSK and shares drop 4%

GlaxoSmithKline yesterday announced its first-quarter financial results. Investors were disappointed and lost interest in the company’s shares, which declined by over 4% (London).  Sales from the London-based group were GBP7.2bn, consistently with expectations, despite the pound strengthening against the dollar….

GSK announces sale of rare disease therapies to Orchard Therapeutics

GlaxoSmithKline has sold its rare disease therapy portfolio to Orchard Therapeutics in exchange for 20% of shares in the Anglo-American biotech and royalties on profits delivered by Orchard with GSK’s treatments. GSK’s move allows the UK-based company to focus on…

New deal for Novartis

It is widely understood that new Novartis CEO Vas Narasimhan has a far more aggressive managerial style than his predecessor Joseph Jiménez. Since Narasimhan was appointed CEO, Novartis has entered into M&A agreements for a total of $25.8bn: it has…

Battle to acquire GlaxoSmithKline’s Horlicks has started

Livemint has reported today that Switzerland-based Nestlé, US-based   Kraft Heinz and Unilever and India-based ITC are the potential buyers of GlaxoSmithKline’s Horlicks asset. Horlicks is one of the most important of GSK’s brands and is likely to be sold for…

Novartis sells GSK its share in JV Consumer Health for $13bn

Novartis and GlaxoSmithKline have jointly announced today, before trading opened in Europe, that GSK has sold 36.5% of JV Consumer Health’s shares to GSK for $13bn. The deal allows GSK to secure one of the largest Consumer Health divisions in…

M&A of Consumer Health units at a stalemate

The market provides with a wide range of opportunities those companies that want to enhance their Consumer Health portfolio through acquisitions. Assets are currently on sale by Germany-based Merck KGaA, intending to dismiss its Consumer Health arm for €4bn, and…

GSK as well renounces to acquire Pfizer’s Consumer Health arm

GlaxoSmithKline informed this morning in a short, concise press release that it will pull out of the process to acquire Pfizer’s Consumer Health division. CEO Emma Walmsley added that the group will keep reviewing other opportunities consistent with its strategy,…

Andrew Witty, former GSK CEO, appointed CEO of Optum

Andrew Witty, former GSK CEO, has found a new job–he will become in June the new CEO of Optum, an arm of UnitedHealth Group that provides healthcare services in the US and employs over 140,000 people worldwide, with over $200m…

Gilead’s Biktarvy (HIV) approved

FDA has granted Gilead approval for its novel drug Biktarvy, for the treatment of HIV. Biktarvy combines the novel inhibitor bictegravir with Gilead’s molecules emtricitabine and tenofovir alafenamide. It is a once-daily treatment–a regimen tested in as many as 4…